HPTN Studies

Our studies strive to prevent HIV infection through the use of antiretroviral drugs, interventions for substance use, behavioral risk reduction, and structural interventions. 

HPTN research studies are developed by protocol teams that include CTU investigators and recognized experts in HIV prevention. As study protocols are developed, they undergo a rigorous intra- and extra-Network review process that ensures compliance with current ethical guidelines and regulatory procedures. Each Study Protocol is available once version 1.0 is approved and distributed to the performance sites.

Study Snapshot

Study Timelines

 

Filter studies by:

HVTN 206/HPTN 114

A phase 2 clinical trial to evaluate the safety, tolerability, pharmacokinetics and neutralization of VRC07-523LS, PGT121.414.LS and PGDM1400LS broadly
neutralizing monoclonal antibodies in adult participants without HIV and in overall good health

Pending

Antibody Mediated Prevention

HPTN 113

Double Prevention: A Vanguard Study of an Integrated Strategy of HIV PrEP and STI PEP for Young Latino Sexual Minority Men (SMM) in the Americas.

Pending

HPTN 112 (39057)

Improving HIV prevention among heterosexual men seeking STI services in Malawi: examining the benefits, acceptability, and associated costs of a systems-navigator-delivered integrated prevention package

Enrolling

Integrated Strategy

HPTN 111 (39062)

Feasibility and Acceptability of a Barbershop Based HIV Prevention Initiative Among Heterosexual Men in Kalangala Islands, Uganda: A Cluster Randomized Trial

Closed to Accrual

Integrated Strategy

HVTN 143/HPTN 109 (39015)

A phase 1- clinical trial to evaluate the safety, tolerability, pharmacokinetics and tolerability of combinations of monoclonal antibodies VRC01.23LS, PGT121.414.LS, and PGDM1400LS administered via intravenous infusion in adults without HIV

Withdrawn

Antibody Mediated Prevention

A5416/HVTN 806/HPTN 108 (39006)

A Phase I, Randomized, Placebo-Controlled Study of the Safety, Antiviral & Immunomodulatory Activity of Broadly Neutralizing Antibodies 3BNC117-LS-J and 10-1074-LS-J in Combination in ART-treated Adults in sub-Saharan Africa Living with HIV during a Monitored Analytical Treatment Interruption

Enrolling

Antibody Mediated Prevention

DMID 19-0004/HPTN 107

A Phase II randomized, observer-blind, placebo-controlled study, to assess efficacy of meningococcal Group B vaccine rMenB+OMV NZ (Bexsero) in preventing gonococcal infection.

Enrolling

HPTN 106 (39002)

A Phase 2 Crossover Study of On Demand PrEP Formulations Comparing Rectal and Oral TFV-Based PrEP Evaluating Extended Safety, Acceptability, and PK/PD

Open to Accrual